Franklin Resources Inc tilts from mega-cap AI to capital-heavy defensives

The biggest buys table reads like a shopping list for long‑duration, scale‑driven cash machines rather than speculative stories. The standout is a new, multi‑billion‑dollar bet that big pharma will be the next structural growth engine.

• AZN (AstraZeneca) arrives as a new position at 0.86% of the book worth $3.49B, instantly one of Franklin’s largest health‑care lines, signaling a belief in late‑stage pipelines and oncology franchises as durable growth, not just a trade.
• ABT (Abbott Laboratories) is boosted aggressively, up 79.5% in shares and about $910.5M in value to $2.06B, despite being slightly underwater at -7.7% versus their average cost — classic averaging‑up in a core medical devices and diagnostics platform they expect to normalize higher.
• GOOGL and GOOG together see heavy incremental capital: Alphabet’s A shares add $856.5M, C shares add $830.3M. That’s not a new AI bet but a conviction that Alphabet’s cash‑rich ad and cloud engine is still under‑priced relative to its role in the AI stack.
• BAC and JPM are both strengthened in size, with Bank of America up 28.0% in shares (about $779.5M more) and JPMorgan up 21.0% (roughly $766.3M). Franklin is clearly building a core in scale, deposit‑rich banks that monetize higher-for-longer rates and credit spreads.
• HON (Honeywell) sees a 32.4% share add and roughly $750.0M more capital, reflecting a preference for diversified industrial automation and aerospace exposure over more cyclically exposed names.
• CSCO (Cisco) gets a 15.7% share increase and an extra $612.3M, backing the boring but necessary networking plumbing that will carry AI and cloud traffic for years.

The pattern: Franklin is happiest adding where fundamentals are tangible and balance sheets are fortress‑like — pharma with broad portfolios, banks with scale funding, and infrastructure‑grade tech.

On the other side, the trims show a manager systematically harvesting winners and paring back crowded "safety" trades to fund higher‑conviction defensives. The largest cuts are in consumer bellwethers and mature industrials whose reratings have largely already happened.

• WMT (Walmart) is cut hard, with shares down 25.2% and about $1.15B taken off the table. With the position still showing a 157.5% gain versus cost, this looks like classic profit‑taking in a fully rerated consumer staple‑in‑disguise.
• JCI (Johnson Controls) is slashed by 28.6% in shares, freeing roughly $849.8M. Given a 186.1% gain, Franklin appears to be acknowledging that the easy money in building‑automation cyclicals is behind them.
• MSFT (Microsoft) is gently trimmed, down 3.9% in shares and about $579.6M in value — a risk‑control move in one of their largest, richly valued AI beneficiaries rather than a thesis reversal.
• RTX (RTX Corporation) and CVX (Chevron) both see double‑digit or high‑single‑digit trims, releasing $440.6M and $289.3M respectively, suggesting less appetite to pay up for defense/aero and integrated oil after strong runs.
• MA (Mastercard) is reduced by 13.2% (about $415.3M), a notable choice given its 151.7% gain — a sign Franklin is comfortable concentrating payments exposure elsewhere, likely via Visa, while de‑crowding a high‑multiple winner.
• PEP (PepsiCo) is cut by 14.3% in shares, with $313.1M trimmed, signaling diminished enthusiasm for slow‑growth staples as a primary risk anchor.

Taken together, the sells look like disciplined capital recycling: lighten the most crowded, expensive quality plays to fund areas where earnings power is less fully priced in.

The sector chart shows a subtle but important pivot. Franklin is still a tech‑first allocator, but the marginal dollar is moving to health care and financials rather than piling into more semis and mega‑cap software.

Technology edges down from 41.1% to 39.94%, even as Franklin tops up Alphabet and Cisco. They’re modestly trimming NVIDIA, Microsoft, Broadcom, and TSMC — not abandoning AI or semis, but rotating from the most bid‑up expressions to cheaper, infrastructure and software angles.

Health care climbs from 10.24% to 12.04%, driven by the new AstraZeneca stake and sizeable adds to Abbott, Merck, Regeneron, and McKesson. That’s a diversified pharma and healthcare‑services basket, pairing innovation risk (biopharma pipelines) with volume‑driven distributors.

Finance rises from 9.72% to 10.64% as Franklin leans harder into JPMorgan, Bank of America, Citigroup, Capital One, Schwab, BlackRock, and Goldman Sachs. The message: own the fee and spread machines that benefit from robust capital markets and non‑zero rates.

Industrials dip slightly from 9.47% to 9.01%, even with bigger Honeywell, Thermo Fisher, Northrop, and GM positions, because of meaningful cuts to RTX and Johnson Controls. Consumer Discretionary (12.43% to 12.0%), Energy (6.47% to 6.12%), Consumer Staples (3.53% to 3.3%), and Real Estate‑labeled payments (2.98% to 2.68%) all drift lower as funding sources.

The net effect is a portfolio that still leans into growth and innovation but with a thicker buffer of regulated, capital‑intensive cash generators.

Put together, Franklin’s 2026‑Q1 moves point to a barbell they think can keep compounding after an unusually strong three years: AI‑driven tech on one side, and regulated, capital‑heavy defensives on the other. They’re not chasing the newest AI story; they’re concentrating on incumbents with the infrastructure, data, and balance sheets to monetize the wave.

On the defensive end, big pharma and diversified health care names now sit alongside scale banks, asset managers, and industrial platforms as the main capital sinks. New money into AstraZeneca and Abbott, plus larger stakes in JPMorgan, Bank of America, Honeywell, and Cisco, suggests Franklin expects steady earnings growth with optionality, but at valuations less extended than the headline AI cohort.

The trims in Walmart, PepsiCo, RTX, Chevron, and Mastercard hint that inexpensive safety is gone in many classic quality franchises. Franklin seems willing to accept slightly more earnings volatility in exchange for better long‑term return potential in pharma, financials, and infrastructure‑grade tech.

Sector‑wise, expect tech to remain the anchor, but future incremental moves will likely refine within that bucket — more toward networks, cloud, and tools rather than simply adding to the highest‑multiple winners. Meanwhile, the rising health‑care and financials sleeves suggest a house view that the next phase of the cycle will reward cash‑rich balance sheets, capital discipline, and regulated oligopolies as much as it has rewarded pure software and semis.